<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/79951901083</prism:url><dc:identifier>SCOPUS_ID:79951901083</dc:identifier><eid>2-s2.0-79951901083</eid><dc:title>Prognostic value of C-reactive protein and other classical factors in patients with advanced non-small cell lung carcinoma treated in routine clinical practice</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>2</citedby-count><prism:publicationName>Zdravniski Vestnik</prism:publicationName><dc:publisher>
                        Slovene Medical Society
                        vestnik@szd.si
                    </dc:publisher><source-id>32772</source-id><prism:issn>15810224 13180347</prism:issn><prism:volume>79</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:startingPage>669</prism:startingPage><prism:endingPage>676</prism:endingPage><prism:pageRange>669-676</prism:pageRange><prism:coverDate>2010-01-01</prism:coverDate><openaccess/><openaccessFlag/><dc:creator><author seq="1" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovčariček T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng">
                        <ce:para>Background: Prognostic factors may help the clinician in treatment decision making. The significance of C-reactive protein (CRP) as a negative prognostic factor has been shown in patients with different malignancies. However, only few studies have analyzed CRP as a prognostic factor in patients with advanced non-small cell lung cancer (NCLCS). The aim of this study was to evaluate the prognostic value of CRP and other prognostic factors in a group of unselected population of patients with advanced NCLSC treated with platinum based chemotherapy. Methods: The retrospective study was conducted by reviewing 53 medical files of advanced NSCLC patients treated with platinum/gemcitabine at the University Clinic Golnik between May 2004 and November 2008. The median age of patients was 65 years, most of them were males (75 %), smokers or ex-smokers (81 %), with performance status 1 ( 64.2 %) and stage IV disease (83 %). The collected data included laboratory characteristics (Hb, platelet count, CRP, LDH) before chemotherapy, information on each individual patient's therapy and outcome. The median number of chemotherapy cycles received was 4 (range, 1-6).Results: The median progression free survival (PFS) for the entire group was 4.8 months (range 0-20 months). Patients with elevated CRP levels (≥ 20 mg/l) had inferior PFS compared to those with low pretreatment CRP values (median PFS 8.4 vs 3.6 months, p=0.006). In Cox univariate regression analysis, CRP (p=0.016, HR=1.008, 95 % CI, 1.001-1.014), Hb (p=0.001, HR= 0.96, 95 %CI, 0.95-0.99), and comorbidity (p=0.051, HR=1.2, 95 %CI, 1.00-1.45) were found to be significant prognostic factors; age, LDH, and platelet count on the other hand were not found to be significant prognostic factors. In multivariate analysis only CRP (p=0.048, HR=0.50, 95 % CI 0.26-0.99) and Hb (p=0.005, HR=0.97, 95 %CI, 0.95-0.99) retained their independent prognostic value. Conclusion: The survival of patients with advanced NSCLC treated by chemotherapy is significantly influenced by the patient's pretreatment CRP and Hb levels, and comorbidity only borderline so. The major advantage of this study is that it was performed on an unselected population of patients, but still uniform with respect to diagnosis, stage and agents used in chemotherapy treatment schedule.</ce:para>
                    </abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/79951901083" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=79951901083&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=79951901083&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovčariček T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="2" auid="12753947800"><ce:initials>N.</ce:initials><ce:indexed-name>TriLLer N.</ce:indexed-name><ce:surname>TriLLer</ce:surname><ce:given-name>Nadja</ce:given-name><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>TriLLer N.</ce:indexed-name><ce:surname>TriLLer</ce:surname><ce:given-name>Nadja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/12753947800</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="3" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="4" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Čufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Čufer T.</ce:indexed-name><ce:surname>Čufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Advanced disease</author-keyword><author-keyword>C-reactive protein (CRP)</author-keyword><author-keyword>HemogLobin (Hb)</author-keyword><author-keyword>Non-smaLL ceLL Lung cancer (NSCLC)</author-keyword><author-keyword>Prognostic factors</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2700" abbrev="MEDI">Medicine (all)</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered day="11" month="11" timestamp="2018-11-11T18:06:19.000019-05:00" year="2018"/><ait:date-sort day="01" month="01" year="2010"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2018 Elsevier B.V., All rights reserved.</copyright><itemidlist>
                    <itemid idtype="PUI">361317492</itemid>
                    <itemid idtype="CAR-ID">272463019</itemid>
                    <itemid idtype="SCOPUS">20183298605</itemid>
                    <itemid idtype="SNEMB">2011016642</itemid>
                    <itemid idtype="SCP">79951901083</itemid>
                    <itemid idtype="SGR">79951901083</itemid>
                </itemidlist><history>
                    <date-created day="08" month="11" timestamp="BST 14:14:30" year="2018"/>
                </history><dbcollection>SCOPUS</dbcollection><dbcollection>SNEMB</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><abstract-language xml:lang="slv" language="Slovenian"/><author-keywords>
                        <author-keyword xml:lang="eng">Advanced disease</author-keyword>
                        <author-keyword xml:lang="eng">C-reactive protein (CRP)</author-keyword>
                        <author-keyword xml:lang="eng">HemogLobin (Hb)</author-keyword>
                        <author-keyword xml:lang="eng">Non-smaLL ceLL Lung cancer (NSCLC)</author-keyword>
                        <author-keyword xml:lang="eng">Prognostic factors</author-keyword>
                    </author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Prognostic value of C-reactive protein and other classical factors in patients with advanced non-small cell lung carcinoma treated in routine clinical practice</titletext></citation-title><author-group><author auid="36992456700" seq="1" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
                            <ce:initials>T.</ce:initials>
                            <ce:indexed-name>Ovčariček T.</ce:indexed-name>
                            <ce:surname>Ovčariček</ce:surname>
                            <ce:given-name>Tanja</ce:given-name>
                        </preferred-name></author><author auid="12753947800" seq="2" type="auth"><ce:initials>N.</ce:initials><ce:indexed-name>TriLLer N.</ce:indexed-name><ce:surname>TriLLer</ce:surname><ce:given-name>Nadja</ce:given-name><preferred-name>
                            <ce:initials>N.</ce:initials>
                            <ce:indexed-name>TriLLer N.</ce:indexed-name>
                            <ce:surname>TriLLer</ce:surname>
                            <ce:given-name>Nadja</ce:given-name>
                        </preferred-name></author><author auid="7004393140" seq="4" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Čufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
                            <ce:initials>T.</ce:initials>
                            <ce:indexed-name>Čufer T.</ce:indexed-name>
                            <ce:surname>Čufer</ce:surname>
                            <ce:given-name>Tanja</ce:given-name>
                        </preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><affiliation-id afid="60078312"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="3" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name>
                            <ce:initials>A.</ce:initials>
                            <ce:indexed-name>Sadikov A.</ce:indexed-name>
                            <ce:surname>Sadikov</ce:surname>
                            <ce:given-name>Aleksander</ce:given-name>
                        </preferred-name></author><affiliation afid="60031106" country="svn" dptid="104580834"><organization>University of Ljubljana</organization><organization>Faculty of Computer and Information Science</organization><affiliation-id afid="60031106" dptid="104580834"/><country>Slovenia</country></affiliation></author-group><correspondence><person>
                        <ce:initials>T.</ce:initials>
                        <ce:indexed-name>Ovcaricek T.</ce:indexed-name>
                        <ce:degrees>Dr.</ce:degrees>
                        <ce:surname>Ovčariček</ce:surname>
                    </person><affiliation country="svn"><organization>Klinika Za Pljučne in Alergijske Bolezni</organization><organization>Bolnišnica Golnik</organization><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng">
                        <ce:para>Background: Prognostic factors may help the clinician in treatment decision making. The significance of C-reactive protein (CRP) as a negative prognostic factor has been shown in patients with different malignancies. However, only few studies have analyzed CRP as a prognostic factor in patients with advanced non-small cell lung cancer (NCLCS). The aim of this study was to evaluate the prognostic value of CRP and other prognostic factors in a group of unselected population of patients with advanced NCLSC treated with platinum based chemotherapy. Methods: The retrospective study was conducted by reviewing 53 medical files of advanced NSCLC patients treated with platinum/gemcitabine at the University Clinic Golnik between May 2004 and November 2008. The median age of patients was 65 years, most of them were males (75 %), smokers or ex-smokers (81 %), with performance status 1 ( 64.2 %) and stage IV disease (83 %). The collected data included laboratory characteristics (Hb, platelet count, CRP, LDH) before chemotherapy, information on each individual patient's therapy and outcome. The median number of chemotherapy cycles received was 4 (range, 1-6).Results: The median progression free survival (PFS) for the entire group was 4.8 months (range 0-20 months). Patients with elevated CRP levels (≥ 20 mg/l) had inferior PFS compared to those with low pretreatment CRP values (median PFS 8.4 vs 3.6 months, p=0.006). In Cox univariate regression analysis, CRP (p=0.016, HR=1.008, 95 % CI, 1.001-1.014), Hb (p=0.001, HR= 0.96, 95 %CI, 0.95-0.99), and comorbidity (p=0.051, HR=1.2, 95 %CI, 1.00-1.45) were found to be significant prognostic factors; age, LDH, and platelet count on the other hand were not found to be significant prognostic factors. In multivariate analysis only CRP (p=0.048, HR=0.50, 95 % CI 0.26-0.99) and Hb (p=0.005, HR=0.97, 95 %CI, 0.95-0.99) retained their independent prognostic value. Conclusion: The survival of patients with advanced NSCLC treated by chemotherapy is significantly influenced by the patient's pretreatment CRP and Hb levels, and comorbidity only borderline so. The major advantage of this study is that it was performed on an unselected population of patients, but still uniform with respect to diagnosis, stage and agents used in chemotherapy treatment schedule.</ce:para>
                    </abstract></abstracts><source country="svn" srcid="32772" type="j"><sourcetitle>Zdravniski Vestnik</sourcetitle><sourcetitle-abbrev>Zdravniski Vestn.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Zdravniski Vestnik</translated-sourcetitle><issn type="electronic">15810224</issn><issn type="print">13180347</issn><volisspag>
                        <voliss issue="10" volume="79"/>
                        <pagerange first="669" last="676"/>
                    </volisspag><publicationyear first="2010"/><publicationdate>
                        <year>2010</year>
                        <date-text>October 2010</date-text>
                    </publicationdate><website>
                        <ce:e-address type="email">http://www.szd.si/user_files/vsebina/Zdravniski_Vestnik/2010/oktober/669-76.pdf</ce:e-address>
                    </website><publisher>
                        <publishername>Slovene Medical Society</publishername>
                        <ce:e-address type="email">vestnik@szd.si</ce:e-address>
                    </publisher></source><enhancement><classificationgroup><classifications type="ASJC">
                            <classification>2700</classification>
                        </classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications></classificationgroup></enhancement></head><tail><bibliography refcount="21">
                    <reference id="1">
                        <ref-info>
                            <refd-itemidlist>
                                <itemid idtype="SGR">79951893014</itemid>
                            </refd-itemidlist>
                            <ref-sourcetitle>Incidenca Raka v Sloveniji 2006 = Cancer Incidence in Slovenia 2006</ref-sourcetitle>
                            <ref-publicationyear first="2009"/>
                            <ref-volisspag>
                                <pagerange first="48"/>
                            </ref-volisspag>
                            <ref-text>Ljubljana: Onkološki inštitut, Epidemiologija in register raka, Register raka za Slovenijo. (Incidenca raka v Sloveniji;)</ref-text>
                        </ref-info>
                        <ref-fulltext>Incidenca raka v Sloveniji 2006 = Cancer incidence in Slovenia 2006. Ljubljana: Onkološki inštitut, Epidemiologija in register raka, Register raka za Slovenijo, 2009. (Incidenca raka v Sloveniji; št. 48).</ref-fulltext>
                    </reference>
                    <reference id="2">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0037050352</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>J.H.</ce:initials>
                                    <ce:indexed-name>Schiller J.H.</ce:indexed-name>
                                    <ce:surname>Schiller</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>D.</ce:initials>
                                    <ce:indexed-name>Harrington D.</ce:indexed-name>
                                    <ce:surname>Harrington</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>C.P.</ce:initials>
                                    <ce:indexed-name>Belani C.P.</ce:indexed-name>
                                    <ce:surname>Belani</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>C.</ce:initials>
                                    <ce:indexed-name>Langer C.</ce:indexed-name>
                                    <ce:surname>Langer</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Sandler A.</ce:indexed-name>
                                    <ce:surname>Sandler</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Krook J.</ce:indexed-name>
                                    <ce:surname>Krook</ce:surname>
                                </author>
                                <author seq="7">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Zhu J.</ce:indexed-name>
                                    <ce:surname>Zhu</ce:surname>
                                </author>
                                <author seq="8">
                                    <ce:initials>D.H.</ce:initials>
                                    <ce:indexed-name>Johnson D.H.</ce:indexed-name>
                                    <ce:surname>Johnson</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>New England Journal of Medicine</ref-sourcetitle>
                            <ref-publicationyear first="2002"/>
                            <ref-volisspag>
                                <voliss issue="2" volume="346"/>
                                <pagerange first="92" last="98"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1056/NEJMoa011954</ref-text>
                        </ref-info>
                        <ref-fulltext>Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, idr. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98. (Pubitemid 34438899)</ref-fulltext>
                    </reference>
                    <reference id="3">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Characterization of lung cancer patients, their actual treatment and survival: Experience in Slovenia</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">22644440742</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>L.</ce:initials>
                                    <ce:indexed-name>Debevec L.</ce:indexed-name>
                                    <ce:surname>Debevec</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Debeljak A.</ce:indexed-name>
                                    <ce:surname>Debeljak</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Erzen J.</ce:indexed-name>
                                    <ce:surname>Eržen</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>V.</ce:initials>
                                    <ce:indexed-name>Kovac V.</ce:indexed-name>
                                    <ce:surname>Kovač</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>I.</ce:initials>
                                    <ce:indexed-name>Kern I.</ce:indexed-name>
                                    <ce:surname>Kern</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
                            <ref-publicationyear first="2005"/>
                            <ref-volisspag>
                                <voliss volume="39"/>
                                <pagerange first="115" last="121"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Debevec L, Debeljak A, Eržen J, Kovač V, Kern I. Characterization of lung cancer patients, their actual treatment and survival: experience in Slovenia. Radiol Oncol 2005; 39: 115-121.</ref-fulltext>
                    </reference>
                    <reference id="4">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0346238665</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>R.</ce:initials>
                                    <ce:indexed-name>Arriagada R.</ce:indexed-name>
                                    <ce:surname>Arriagada</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>B.</ce:initials>
                                    <ce:indexed-name>Bergman B.</ce:indexed-name>
                                    <ce:surname>Bergman</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Dunant A.</ce:indexed-name>
                                    <ce:surname>Dunant</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>T.</ce:initials>
                                    <ce:indexed-name>Le Chevalier T.</ce:indexed-name>
                                    <ce:surname>Le Chevalier</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>J.-P.</ce:initials>
                                    <ce:indexed-name>Pignon J.-P.</ce:indexed-name>
                                    <ce:surname>Pignon</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Vansteenkiste J.</ce:indexed-name>
                                    <ce:surname>Vansteenkiste</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>New England Journal of Medicine</ref-sourcetitle>
                            <ref-publicationyear first="2004"/>
                            <ref-volisspag>
                                <voliss issue="4" volume="350"/>
                                <pagerange first="351" last="360"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1056/NEJMoa031644</ref-text>
                        </ref-info>
                        <ref-fulltext>Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, idr. Cisplatin.based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360. (Pubitemid 38101630)</ref-fulltext>
                    </reference>
                    <reference id="5">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">34247866512</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Zwitter M.</ce:indexed-name>
                                    <ce:surname>Zwitter</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>V.</ce:initials>
                                    <ce:indexed-name>Kovac V.</ce:indexed-name>
                                    <ce:surname>Kovac</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>U.</ce:initials>
                                    <ce:indexed-name>Smrdel U.</ce:indexed-name>
                                    <ce:surname>Smrdel</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>P.</ce:initials>
                                    <ce:indexed-name>Strojan P.</ce:indexed-name>
                                    <ce:surname>Strojan</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Journal of Thoracic Oncology</ref-sourcetitle>
                            <ref-publicationyear first="2006"/>
                            <ref-volisspag>
                                <voliss issue="7" volume="1"/>
                                <pagerange first="662" last="666"/>
                            </ref-volisspag>
                            <ref-text>PII 0124389420060900000010</ref-text>
                        </ref-info>
                        <ref-fulltext>Zwitter M, Kovač V, Smrdel U, Strojan P. Gemcitabin, cisplatin, and hyperfracionated accelerated radiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 662-666. (Pubitemid 47163953)</ref-fulltext>
                    </reference>
                    <reference id="6">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Prognostic factors in non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0036384579</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>M.D.</ce:initials>
                                    <ce:indexed-name>Brundage M.D.</ce:indexed-name>
                                    <ce:surname>Brundage</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>D.</ce:initials>
                                    <ce:indexed-name>Davies D.</ce:indexed-name>
                                    <ce:surname>Davies</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>W.J.</ce:initials>
                                    <ce:indexed-name>MacKillop W.J.</ce:indexed-name>
                                    <ce:surname>MacKillop</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Chest</ref-sourcetitle>
                            <ref-publicationyear first="2002"/>
                            <ref-volisspag>
                                <voliss volume="122"/>
                                <pagerange first="1037" last="1057"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Brundage M.D, Davies D, Mackillop W.J. Prognostic Factors in Non-small Cell Lung Cancer. Chest 2002; 122; 1037-1057.</ref-fulltext>
                    </reference>
                    <reference id="7">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Baseline C -Reactive protein is associated with incident cancer and survival in patients with cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">65549122953</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>K.H.</ce:initials>
                                    <ce:indexed-name>Allin K.H.</ce:indexed-name>
                                    <ce:surname>Allin</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>S.E.</ce:initials>
                                    <ce:indexed-name>Bojesen S.E.</ce:indexed-name>
                                    <ce:surname>Bojesen</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>B.G.</ce:initials>
                                    <ce:indexed-name>Nordestgaard B.G.</ce:indexed-name>
                                    <ce:surname>Nordestgaard</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
                            <ref-publicationyear first="2009"/>
                            <ref-volisspag>
                                <voliss volume="27"/>
                                <pagerange first="2217" last="2224"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Allin KH, Bojesen SE, Nordestgaard BG. Baseline C -Reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-2224.</ref-fulltext>
                    </reference>
                    <reference id="8">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>A systematic review of the association between circulating concentartions of C reactive protein and cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">34250873779</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>K.</ce:initials>
                                    <ce:indexed-name>Heikkila K.</ce:indexed-name>
                                    <ce:surname>Heikkilä</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>S.</ce:initials>
                                    <ce:indexed-name>Ebrahim S.</ce:indexed-name>
                                    <ce:surname>Ebrahim</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>D.A.</ce:initials>
                                    <ce:indexed-name>Lawlor D.A.</ce:indexed-name>
                                    <ce:surname>Lawlor</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>J Epidemiol Community Health</ref-sourcetitle>
                            <ref-publicationyear first="2007"/>
                            <ref-volisspag>
                                <voliss volume="61"/>
                                <pagerange first="824" last="833"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentartions of C reactive protein and cancer. J Epidemiol Community Health 2007; 61; 824-833.</ref-fulltext>
                    </reference>
                    <reference id="9">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Plasma C-reactive protein and risk of cancer: A prospective study from Greece</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">33644802473</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>D.</ce:initials>
                                    <ce:indexed-name>Trichopoulos D.</ce:indexed-name>
                                    <ce:surname>Trichopoulos</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>T.</ce:initials>
                                    <ce:indexed-name>Psaltopoulou T.</ce:indexed-name>
                                    <ce:surname>Psaltopoulou</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>P.</ce:initials>
                                    <ce:indexed-name>Orfanos P.</ce:indexed-name>
                                    <ce:surname>Orfanos</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Trichopoulou A.</ce:indexed-name>
                                    <ce:surname>Trichopoulou</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>P.</ce:initials>
                                    <ce:indexed-name>Boffetta P.</ce:indexed-name>
                                    <ce:surname>Boffetta</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Cancer Epidemiology Biomarkers and Prevention</ref-sourcetitle>
                            <ref-publicationyear first="2006"/>
                            <ref-volisspag>
                                <voliss issue="2" volume="15"/>
                                <pagerange first="381" last="384"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1158/1055-9965.EPI-05-0626</ref-text>
                        </ref-info>
                        <ref-fulltext>Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-Reactive Protein and Risk of Cancer: a prospective Study from Greece. Cancer Epidemiol Biomarkers Prev 2006: 15: 381-384. (Pubitemid 43348407)</ref-fulltext>
                    </reference>
                    <reference id="10">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Associations of circulating C-reactive protein and interleukin-6 with cancer risk: Findings from two prospective cohorts and meta-analysis</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">58249122522</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>K.</ce:initials>
                                    <ce:indexed-name>Heikkila K.</ce:indexed-name>
                                    <ce:surname>Heikkilä</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>R.</ce:initials>
                                    <ce:indexed-name>Harris R.</ce:indexed-name>
                                    <ce:surname>Harris</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>G.</ce:initials>
                                    <ce:indexed-name>Lowe G.</ce:indexed-name>
                                    <ce:surname>Lowe</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Rumley A.</ce:indexed-name>
                                    <ce:surname>Rumley</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Yarnell J.</ce:indexed-name>
                                    <ce:surname>Yarnell</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Gallacher J.</ce:indexed-name>
                                    <ce:surname>Gallacher</ce:surname>
                                </author>
                                <et-al/>
                            </ref-authors>
                            <ref-sourcetitle>Cancer Causes Control</ref-sourcetitle>
                            <ref-publicationyear first="2009"/>
                            <ref-volisspag>
                                <voliss volume="20"/>
                                <pagerange first="15" last="26"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, idr. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and meta-analysis. Cancer Causes Control 2009; 20: 15-26.</ref-fulltext>
                    </reference>
                    <reference id="11">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">26444586236</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>D.</ce:initials>
                                    <ce:indexed-name>Il'yasova D.</ce:indexed-name>
                                    <ce:surname>Il'yasova</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>L.H.</ce:initials>
                                    <ce:indexed-name>Colbert L.H.</ce:indexed-name>
                                    <ce:surname>Colbert</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>T.B.</ce:initials>
                                    <ce:indexed-name>Harris T.B.</ce:indexed-name>
                                    <ce:surname>Harris</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>A.B.</ce:initials>
                                    <ce:indexed-name>Newman A.B.</ce:indexed-name>
                                    <ce:surname>Newman</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>D.C.</ce:initials>
                                    <ce:indexed-name>Bauer D.C.</ce:indexed-name>
                                    <ce:surname>Bauer</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>S.</ce:initials>
                                    <ce:indexed-name>Satterfield S.</ce:indexed-name>
                                    <ce:surname>Satterfield</ce:surname>
                                </author>
                                <author seq="7">
                                    <ce:initials>S.B.</ce:initials>
                                    <ce:indexed-name>Kritchevsky S.B.</ce:indexed-name>
                                    <ce:surname>Kritchevsky</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Cancer Epidemiology Biomarkers and Prevention</ref-sourcetitle>
                            <ref-publicationyear first="2005"/>
                            <ref-volisspag>
                                <voliss issue="10" volume="14"/>
                                <pagerange first="2413" last="2418"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1158/1055-9965.EPI-05-0316</ref-text>
                        </ref-info>
                        <ref-fulltext>Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, idr. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-2418. (Pubitemid 41437845)</ref-fulltext>
                    </reference>
                    <reference id="12">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">34247155282</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>C.</ce:initials>
                                    <ce:indexed-name>Siemes C.</ce:indexed-name>
                                    <ce:surname>Siemes</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>L.E.</ce:initials>
                                    <ce:indexed-name>Visser L.E.</ce:indexed-name>
                                    <ce:surname>Visser</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>J.W.</ce:initials>
                                    <ce:indexed-name>Coebergh J.W.</ce:indexed-name>
                                    <ce:surname>Coebergh</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>T.A.W.</ce:initials>
                                    <ce:indexed-name>Splinter T.A.W.</ce:indexed-name>
                                    <ce:surname>Splinter</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>J.C.M.</ce:initials>
                                    <ce:indexed-name>Witteman J.C.M.</ce:indexed-name>
                                    <ce:surname>Witteman</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>A.G.</ce:initials>
                                    <ce:indexed-name>Uitterlinden A.G.</ce:indexed-name>
                                    <ce:surname>Uitterlinden</ce:surname>
                                </author>
                                <author seq="7">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Hofman A.</ce:indexed-name>
                                    <ce:surname>Hofman</ce:surname>
                                </author>
                                <author seq="8">
                                    <ce:initials>H.A.P.</ce:initials>
                                    <ce:indexed-name>Pols H.A.P.</ce:indexed-name>
                                    <ce:surname>Pols</ce:surname>
                                </author>
                                <author seq="9">
                                    <ce:initials>B.H.Ch.</ce:initials>
                                    <ce:indexed-name>Stricker B.H.Ch.</ce:indexed-name>
                                    <ce:surname>Stricker</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle>
                            <ref-publicationyear first="2006"/>
                            <ref-volisspag>
                                <voliss issue="33" volume="24"/>
                                <pagerange first="5216" last="5222"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1200/JCO.2006.07.1381</ref-text>
                        </ref-info>
                        <ref-fulltext>Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, idr al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 2006; 24: 5216-5222. (Pubitemid 46631365)</ref-fulltext>
                    </reference>
                    <reference id="13">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Prognostic Significance of C-Reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">67049168039</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Koch A.</ce:indexed-name>
                                    <ce:surname>Koch</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>H.</ce:initials>
                                    <ce:indexed-name>Fohlin H.</ce:indexed-name>
                                    <ce:surname>Fohlin</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>S.</ce:initials>
                                    <ce:indexed-name>Sorenson S.</ce:indexed-name>
                                    <ce:surname>Sorenson</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>J Thorac Oncol</ref-sourcetitle>
                            <ref-publicationyear first="2009"/>
                            <ref-volisspag>
                                <voliss volume="4"/>
                                <pagerange first="326" last="332"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Koch A, Fohlin H, Sorenson S. Prognostic Significance of C-Reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009; 4: 326-332.</ref-fulltext>
                    </reference>
                    <reference id="14">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0141887346</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>L.M.</ce:initials>
                                    <ce:indexed-name>Forrest L.M.</ce:indexed-name>
                                    <ce:surname>Forrest</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>D.C.</ce:initials>
                                    <ce:indexed-name>McMillan D.C.</ce:indexed-name>
                                    <ce:surname>McMillan</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>C.S.</ce:initials>
                                    <ce:indexed-name>McArdle C.S.</ce:indexed-name>
                                    <ce:surname>McArdle</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>W.J.</ce:initials>
                                    <ce:indexed-name>Angerson W.J.</ce:indexed-name>
                                    <ce:surname>Angerson</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>D.J.</ce:initials>
                                    <ce:indexed-name>Dunlop D.J.</ce:indexed-name>
                                    <ce:surname>Dunlop</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>British Journal of Cancer</ref-sourcetitle>
                            <ref-publicationyear first="2003"/>
                            <ref-volisspag>
                                <voliss issue="6" volume="89"/>
                                <pagerange first="1028" last="1030"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1038/sj.bjc.6601242</ref-text>
                        </ref-info>
                        <ref-fulltext>Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cummulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89: 1028-1030 (Pubitemid 37239206)</ref-fulltext>
                    </reference>
                    <reference id="15">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>The systemic inflammatory response weight loss, performance status and survival in patients with inoperable non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0037194349</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>H.R.</ce:initials>
                                    <ce:indexed-name>Scott H.R.</ce:indexed-name>
                                    <ce:surname>Scott</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>D.C.</ce:initials>
                                    <ce:indexed-name>McMillan D.C.</ce:indexed-name>
                                    <ce:surname>McMillan</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>L.M.</ce:initials>
                                    <ce:indexed-name>Forrest L.M.</ce:indexed-name>
                                    <ce:surname>Forrest</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>D.J.F.</ce:initials>
                                    <ce:indexed-name>Brown D.J.F.</ce:indexed-name>
                                    <ce:surname>Brown</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>C.S.</ce:initials>
                                    <ce:indexed-name>McArdle C.S.</ce:indexed-name>
                                    <ce:surname>McArdle</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>R.</ce:initials>
                                    <ce:indexed-name>Milroy R.</ce:indexed-name>
                                    <ce:surname>Milroy</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Br J Cancer</ref-sourcetitle>
                            <ref-publicationyear first="2002"/>
                            <ref-volisspag>
                                <voliss volume="87"/>
                                <pagerange first="264" last="267"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, Milroy R. The systemic inflammatory response weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002; 87: 264-267.</ref-fulltext>
                    </reference>
                    <reference id="16">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Correlation of C-reactive protein with survival and radiographic response to firstline platinum-based chemotherapy in advanced non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">57449117094</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>S.</ce:initials>
                                    <ce:indexed-name>Wilop S.</ce:indexed-name>
                                    <ce:surname>Wilop</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Crysandt M.</ce:indexed-name>
                                    <ce:surname>Crysandt</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Bendel M.</ce:indexed-name>
                                    <ce:surname>Bendel</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>A.H.</ce:initials>
                                    <ce:indexed-name>Mahnken A.H.</ce:indexed-name>
                                    <ce:surname>Mahnken</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>R.</ce:initials>
                                    <ce:indexed-name>Osieka R.</ce:indexed-name>
                                    <ce:surname>Osieka</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>E.</ce:initials>
                                    <ce:indexed-name>Jost E.</ce:indexed-name>
                                    <ce:surname>Jost</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Onkologie</ref-sourcetitle>
                            <ref-publicationyear first="2008"/>
                            <ref-volisspag>
                                <voliss volume="31"/>
                                <pagerange first="665" last="670"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to firstline platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008; 31: 665-670.</ref-fulltext>
                    </reference>
                    <reference id="17">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Preoperative serum C-reactive protein level in non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">34547761399</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Hara M.</ce:indexed-name>
                                    <ce:surname>Hara</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>Y.</ce:initials>
                                    <ce:indexed-name>Matsuzaki Y.</ce:indexed-name>
                                    <ce:surname>Matsuzaki</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>T.</ce:initials>
                                    <ce:indexed-name>Shimuzu T.</ce:indexed-name>
                                    <ce:surname>Shimuzu</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Tomita M.</ce:indexed-name>
                                    <ce:surname>Tomita</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>T.</ce:initials>
                                    <ce:indexed-name>Ayabe T.</ce:indexed-name>
                                    <ce:surname>Ayabe</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>Y.</ce:initials>
                                    <ce:indexed-name>Enomoto Y.</ce:indexed-name>
                                    <ce:surname>Enomoto</ce:surname>
                                </author>
                                <author seq="7">
                                    <ce:initials>T.</ce:initials>
                                    <ce:indexed-name>Onitsuka T.</ce:indexed-name>
                                    <ce:surname>Onitsuka</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Anticancer Research</ref-sourcetitle>
                            <ref-publicationyear first="2007"/>
                            <ref-volisspag>
                                <voliss issue="4" volume="27"/>
                                <pagerange first="3001" last="3004"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, idr. Preoperative serum C-reactive protein level in non-small-cell lung cancer. Anticancer Res 2007; 27: 3001-3004. (Pubitemid 47228036)</ref-fulltext>
                    </reference>
                    <reference id="18">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">33744830039</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>J.M.</ce:initials>
                                    <ce:indexed-name>Jones J.M.</ce:indexed-name>
                                    <ce:surname>Jones</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>N.C.</ce:initials>
                                    <ce:indexed-name>McGonigle N.C.</ce:indexed-name>
                                    <ce:surname>McGonigle</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>McAnespie M.</ce:indexed-name>
                                    <ce:surname>McAnespie</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>G.W.</ce:initials>
                                    <ce:indexed-name>Cran G.W.</ce:indexed-name>
                                    <ce:surname>Cran</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>A.N.</ce:initials>
                                    <ce:indexed-name>Graham A.N.</ce:indexed-name>
                                    <ce:surname>Graham</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Lung Cancer</ref-sourcetitle>
                            <ref-publicationyear first="2006"/>
                            <ref-volisspag>
                                <voliss issue="1" volume="53"/>
                                <pagerange first="97" last="101"/>
                            </ref-volisspag>
                            <ref-text>DOI 10.1016/j.lungcan.2006.03.012, PII S016950020600170X</ref-text>
                        </ref-info>
                        <ref-fulltext>Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer.Lung Cancer 2006; 53: 97-101. (Pubitemid 43831357)</ref-fulltext>
                    </reference>
                    <reference id="19">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Survival determinants in extensive-stage non-small-cell lung cancer. the Southwest Oncology Group experience</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">0025826624</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>K.S.</ce:initials>
                                    <ce:indexed-name>Albain K.S.</ce:indexed-name>
                                    <ce:surname>Albain</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>J.J.</ce:initials>
                                    <ce:indexed-name>Crowley J.J.</ce:indexed-name>
                                    <ce:surname>Crowley</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>M.</ce:initials>
                                    <ce:indexed-name>Leblanc M.</ce:indexed-name>
                                    <ce:surname>Leblanc</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>R.B.</ce:initials>
                                    <ce:indexed-name>Livingston R.B.</ce:indexed-name>
                                    <ce:surname>Livingston</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
                            <ref-publicationyear first="1991"/>
                            <ref-volisspag>
                                <voliss volume="9"/>
                                <pagerange first="1618" last="1626"/>
                            </ref-volisspag>
                        </ref-info>
                        <ref-fulltext>Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.</ref-fulltext>
                    </reference>
                    <reference id="20">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Phase II study of two dose shedules of C.E.R.A. (continuous erythropoetin receptor activators) in anemic patients with advanced non-small cell lung cancer receiving chemotherapy</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">33947585511</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>V.</ce:initials>
                                    <ce:indexed-name>Hirsch V.</ce:indexed-name>
                                    <ce:surname>Hirsch</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>J.</ce:initials>
                                    <ce:indexed-name>Glospy J.</ce:indexed-name>
                                    <ce:surname>Glospy</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>P.</ce:initials>
                                    <ce:indexed-name>Mainwaring P.</ce:indexed-name>
                                    <ce:surname>Mainwaring</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>C.</ce:initials>
                                    <ce:indexed-name>Manegold C.</ce:indexed-name>
                                    <ce:surname>Manegold</ce:surname>
                                </author>
                                <author seq="5">
                                    <ce:initials>R.</ce:initials>
                                    <ce:indexed-name>Ramlau R.</ce:indexed-name>
                                    <ce:surname>Ramlau</ce:surname>
                                </author>
                                <author seq="6">
                                    <ce:initials>J.E.</ce:initials>
                                    <ce:indexed-name>Eid J.E.</ce:indexed-name>
                                    <ce:surname>Eid</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Trials</ref-sourcetitle>
                            <ref-publicationyear first="2007"/>
                            <ref-volisspag>
                                <voliss volume="8"/>
                                <pagerange first="8"/>
                            </ref-volisspag>
                            <ref-website>
                                <ce:e-address type="email">http://www.trialsjournal.com/content/8/1/8</ce:e-address>
                            </ref-website>
                        </ref-info>
                        <ref-fulltext>Hirsch V, Glospy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II study of two dose shedules of C.E.R.A. (continuous erythropoetin receptor activators) in anemic patients with advanced non-small cell lung cancer receiving chemotherapy. Trials 2007; 8: 8. Dosegljivo na: http://www. trialsjournal.com/content/8/1/8.</ref-fulltext>
                    </reference>
                    <reference id="21">
                        <ref-info>
                            <ref-title>
                                <ref-titletext>Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer</ref-titletext>
                            </ref-title>
                            <refd-itemidlist>
                                <itemid idtype="SGR">33846615109</itemid>
                            </refd-itemidlist>
                            <ref-authors>
                                <author seq="1">
                                    <ce:initials>C.</ce:initials>
                                    <ce:indexed-name>Gridelli C.</ce:indexed-name>
                                    <ce:surname>Gridelli</ce:surname>
                                </author>
                                <author seq="2">
                                    <ce:initials>P.</ce:initials>
                                    <ce:indexed-name>Maione P.</ce:indexed-name>
                                    <ce:surname>Maione</ce:surname>
                                </author>
                                <author seq="3">
                                    <ce:initials>D.</ce:initials>
                                    <ce:indexed-name>Comunale D.</ce:indexed-name>
                                    <ce:surname>Comunale</ce:surname>
                                </author>
                                <author seq="4">
                                    <ce:initials>A.</ce:initials>
                                    <ce:indexed-name>Rossi A.</ce:indexed-name>
                                    <ce:surname>Rossi</ce:surname>
                                </author>
                            </ref-authors>
                            <ref-sourcetitle>Cancer Control</ref-sourcetitle>
                            <ref-publicationyear first="2007"/>
                            <ref-volisspag>
                                <voliss issue="1" volume="14"/>
                                <pagerange first="57" last="62"/>
                            </ref-volisspag>
                            <ref-website>
                                <ce:e-address type="email">http://www.moffitt.org/moffittapps/ccj//v14n1/pdf/57.pdf</ce:e-address>
                            </ref-website>
                        </ref-info>
                        <ref-fulltext>Gridelli C, Maione P, Comunale D, Rossi A. Adjuvant chemotherapy in eldery patients with non-small-cell lung cancer. Cancer Control 2007; 14: 57-62. (Pubitemid 46172394)</ref-fulltext>
                    </reference>
                </bibliography></tail></bibrecord></item></abstracts-retrieval-response>